Last reviewed · How we verify
ENX-102
At a glance
| Generic name | ENX-102 |
|---|---|
| Also known as | ENX-102 low-dose, ENX-102 mid-dose, ENX-102 high-dose |
| Sponsor | Engrail Therapeutics INC |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate the Efficacy and Safety of ENX-102 in Participants With Social Anxiety Disorder (PHASE2)
- ENCALM: A Study of ENX-102 as a Monotherapy Treatment in Patients With Generalized Anxiety Disorder (PHASE2)
- A Dose-Response Safety Study of ENX-102 in Patients With GAD (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ENX-102 CI brief — competitive landscape report
- ENX-102 updates RSS · CI watch RSS
- Engrail Therapeutics INC portfolio CI